These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15075331)

  • 1. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
    Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
    FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.
    Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG
    J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
    Garrett TP; Burgess AW; Gan HK; Luwor RB; Cartwright G; Walker F; Orchard SG; Clayton AH; Nice EC; Rothacker J; Catimel B; Cavenee WK; Old LJ; Stockert E; Ritter G; Adams TE; Hoyne PA; Wittrup D; Chao G; Cochran JR; Luo C; Lou M; Huyton T; Xu Y; Fairlie WD; Yao S; Scott AM; Johns TG
    Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5082-7. PubMed ID: 19289842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of Ch806 mimotopes.
    Yang L; Jiang H; Shi B; Wang H; Li J; Wang H; Yao M; Li Z
    Cancer Immunol Immunother; 2010 Oct; 59(10):1481-7. PubMed ID: 20544195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.
    Gan HK; Walker F; Burgess AW; Rigopoulos A; Scott AM; Johns TG
    J Biol Chem; 2007 Feb; 282(5):2840-50. PubMed ID: 17092939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.
    Walker F; Orchard SG; Jorissen RN; Hall NE; Zhang HH; Hoyne PA; Adams TE; Johns TG; Ward C; Garrett TP; Zhu HJ; Nerrie M; Scott AM; Nice EC; Burgess AW
    J Biol Chem; 2004 May; 279(21):22387-98. PubMed ID: 15016810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
    Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
    Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
    Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
    Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
    Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
    Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.